In Re Accutane Litigation

233 N.C. App. 319
CourtCourt of Appeals of North Carolina
DecidedApril 1, 2014
Docket13-754
StatusPublished
Cited by3 cases

This text of 233 N.C. App. 319 (In Re Accutane Litigation) is published on Counsel Stack Legal Research, covering Court of Appeals of North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Accutane Litigation, 233 N.C. App. 319 (N.C. Ct. App. 2014).

Opinion

STEELMAN, Judge.

Where the defendant in a New Jersey mass tort litigation subpoenas a North Carolina witness for a deposition, the North Carolina trial court’s protective order was an interlocutory order. Where the witness *320 failed to allege any substantial right that would be jeopardized absent immediate review, but instead speculates that if certain fact scenarios occur in the future his rights might be implicated, his appeal must be dismissed.

Í. Factual and Procedural Background

In the early 1980s Hoffmann-LaRoche, Inc., began marketing Accutane, the brand name for the drug isotretinoin, which is used to treat severe acne. Beginning in 2003, lawsuits were filed alleging that the use of Accutane had caused inflammatory bowel disease. In May 2005, the New Jersey Supreme Court ordered that the litigation pertaining to Accutane be administered as a mass tort, and as of “July 2012, there [were] nearly 8000 cases listed on New Jersey’s Accutane mass tort fist.” Sager v. Hoffman-La Roche, Inc., 2012 N.J. Super. Unpub. LEXIS 1885 *9 fn2, petition for certification denied, 213 N. J. 568, 65 A.3d 835 (2013).

Dr. Kappelman is an Assistant Professor on the faculty of the Medical School of the University of North Carolina at Chapel Hill, whose duties include treating patients, conducting research studies, and publishing the results of his studies. This is primarily in the field of pediatric gastro-enterology. He is not a party in the Accutane litigation and has not consulted with any of the parties. However, Dr. Kappelman was a co-author of “A [Causal] Association between Isotretinoin and Inflammatory Bowel Disease Has Yet to Be Established,” an article published in 2009 in The American Journal of Gastroenterology (TAJG). Dr. Kappelman discussed the article in a March 2010 interview published in the Gastroenterology & Hepatology journal. He was also a co-author of “Isotretinoin Use and Risk of Inflammatory Bowel Disease: A Case Control Study,” an article published in September of 2010 in TAJG. This article resulted in a letter to the editor by Hoffmann-LaRoche employees, published in TAJG in May 2011, which criticized the methodology described in the September 2010 article. This issue also contains a letter by Dr. Kappelman responding to the criticisms. Plaintiffs in the Accutane litigation have cited some of Dr. Kappelman’s work in support of a causal fink between Accutane and inflammatory bowel disease. When Hoffmann-LaRoche sought to introduce other writings by Dr. Kappelman to rebut plaintiffs’ evidence, New Jersey trial judge Carol E. Higbee ruled that Hoffmann-LaRoche could not introduce this evidence in documentary form but would have to depose Dr. Kappelman.

Based upon a subpoena ad testificandum filed 15 February 2013 by the Superior Court of Atlantic County, New Jersey, the Clerk of the Superior Court of Orange County, North Carolina, issued a subpoena on *321 15 February 2013, for Dr. Kappelman to be deposed on 14 March 2013 in Chapel Hill. On 5 March 2013. Dr. Kappelman filed a motion to quash the subpoena and for a protective order. The motion was heard on 8 April 2013, and on 16 April 2013 the trial court entered a protective order barring Hoffmann-LaRoche from deposing Dr. Kappelman as an “involuntary non-fact” witness, but stating that he could be deposed as an expert witness without violating the protective order. The order states in relevant part: 1

Applying a balancing test set forth in Anker v. G.D. Searle & Co., 126 F.R.D. 515, 518 (M.D.N.C. 1989), the Court finds that Dr. Kappelman is not a party to this litigation; he is an independent researcher and has demonstrated that he is [an] involuntary non-fact witness who has substantially demonstrated that his deposition would result in undue hardship and would be substantially burdensome to him as ah involuntary non-fact witness in the context of the defendants’ mass tort litigation in New Jersey involving 7,700 pending claims; and, no party in that litigation has retained Dr. Kappelman as an expert. Therefore, Dr. Kappelman’s motion for a protective order is granted with respect to future subpoenas to Dr. Kappelman as an involuntary non-fact witness.
Notwithstanding this ruling, defendants may have subpoenas issued to Dr. Kappelman as an expert witness without violating this protective order, and Dr. Kappelman will be required to appear for a deposition if he is subpoenaed as an expert.

The parties agreed during the hearing that defendant had subpoenaed Dr. Kappelman as a fact witness; however, the order does not address whether Dr. Kappelman may be deposed as a fact witness, but only bars defendants from deposing Dr. Kappelman as “an involuntary non-fact witness.” And, although the most common type of “non-fact *322 witness” is an expert witness, 2 the order also states that the protective order would not bar Hoffmann-LaRoche from issuing a subpoena for Dr. Kappelman as an expert witness. As a result, the only legal effect of the protective order is to prevent defendants from deposing Dr. Kappelman as an involuntary non-fact lay witness. Dr. Kappelman argues in his response to Hoffmann-LaRoche’s dismissal motion that the trial court’s order is “muddled” and “self-contradictory.” However, Dr. Kappelman did not file a motion seeking clarification of the order. See Alston v. Fed. Express Corp., 200 N.C. App. 420, 423-24, 684 S.E.2d 705, 707 (2009) (“Pursuant to Rule 60(b)(6)’s ‘grand reservoir of equitable power,’ the trial court had jurisdiction to revisit its order so that its intentions could be made clear.”) (quoting In re Oxford Plastics v. Goodson, 74 N.C. App. 256, 259, 328 S.E.2d 7, 9 (1985)).

Dr. Kappelman appeals.

II. Hoffmann-LaRoche’s Motion to Dismiss Appeal

On 23 July 2013 Hoffmann-LaRoche filed a motion seeking dismissal of Dr. Kappelman’s appeal, arguing that Dr. Kappelman had appealed from an interlocutory order that did not affect a substantial right. We agree.

A. Interlocutory Nature of Anneal

According to N.C. Gen. Stat. § 1A-1, Rule 54(a), a “judgment is either interlocutoiy or the final determination of the rights of the parties.” “ ‘An interlocutory order is one made during the pendency of an action, which does not dispose of the case, but leaves it for further action by the trial court in order to settle and determine the entire controversy.’ ” Hill v. StubHub, Inc., _N.C. App. _, _, 727 S.E.2d 550, 553-54 (2012) (quoting Veazey v. Durham, 231 N.C. 357, 362, 57 S.E.2d 377, 381 (1950)), disc. review denied, 366 N.C. 424, 736 S.E.2d 757 (2013).

On appeal, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Valenzuela v. Delhaize Am., LLC
Court of Appeals of North Carolina, 2026
Hall v. Wilmington Health
Court of Appeals of North Carolina, 2022
In re: M.B.
800 S.E.2d 757 (Court of Appeals of North Carolina, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
233 N.C. App. 319, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-accutane-litigation-ncctapp-2014.